In this large trial of patients with acute coronary syndrome undergoing PCI, they were randomized to high or low dose ASA (325mg vs 81mg) and high or low clopidogrel (600mg, followed by 150mg for a week, then 75mg/day, versus 300mg, followed by 75mg/day). The high dose clopidogrel group had lower 30 day CV death/MI/stroke (3.9% vs 4.5%), but ASA dose did not affect the primary outcome. High dose clopidogrel did increase the risk of major bleeding (1.6% vs 1.1%) (abstract)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.